Which has stronger valuation and earnings, BIO or RGEN?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 4.00 $759.90M $8.25 46.87 Repligen $738.26M 13.84 $48.89M $0.73 247.92

Does the media prefer BIO or RGEN?

In the previous week, Repligen had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for Repligen and 13 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.37 beat Bio-Rad Laboratories' score of 0.02 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repligen 16 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BIO or TECH?

In the previous week, Bio-Techne had 14 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 27 mentions for Bio-Techne and 13 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 1.50 beat Bio-Rad Laboratories' score of 0.02 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Techne 21 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Very Positive

Does the media prefer BIO or A?

In the previous week, Agilent Technologies had 63 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 76 mentions for Agilent Technologies and 13 mentions for Bio-Rad Laboratories. Agilent Technologies' average media sentiment score of 1.16 beat Bio-Rad Laboratories' score of 0.02 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agilent Technologies 44 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMN or BIO?

In the previous week, AMN Healthcare Services had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for AMN Healthcare Services and 13 mentions for Bio-Rad Laboratories. AMN Healthcare Services' average media sentiment score of 0.48 beat Bio-Rad Laboratories' score of 0.02 indicating that AMN Healthcare Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BIO.B or BIO?

Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 11.21%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bio-Rad Laboratories 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher valuation and earnings, BIO.B or BIO?

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.78 $759.90M $8.25 44.25 Bio-Rad Laboratories $2.58B 4.00 $759.90M $8.25 46.87

Is BIO.B or BIO more profitable?

Company Net Margins Return on Equity Return on Assets Bio-Rad Laboratories 8.59% 3.54% 2.48% Bio-Rad Laboratories 8.59% 3.54% 2.48%

Bio-Rad Laboratories (BIO) Competitors

$386.68 -1.02 (-0.26%)

As of 08/31/2026 03:58 PM Eastern

Compare

BIO vs. RGEN, TECH, A, AMN, and BIO.B

Should you buy Bio-Rad Laboratories stock or one of its competitors? Bio-Rad Laboratories's main competitors and comparable companies include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO.B). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Bio-Rad Laboratories compare to Repligen?

Bio-Rad Laboratories (NYSE:BIO) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Repligen had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for Repligen and 13 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.37 beat Bio-Rad Laboratories' score of 0.02 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Repligen	16 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	4.00	$759.90M	$8.25	46.87
Repligen	$738.26M	13.84	$48.89M	$0.73	247.92

Bio-Rad Laboratories presently has a consensus target price of $343.33, indicating a potential downside of 11.21%. Repligen has a consensus target price of $166.43, indicating a potential downside of 8.04%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Repligen	5.29%	5.30%	3.79%

Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

Repligen beats Bio-Rad Laboratories on 11 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Techne?

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Bio-Techne had 14 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 27 mentions for Bio-Techne and 13 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 1.50 beat Bio-Rad Laboratories' score of 0.02 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Techne	21 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Very Positive

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	4.00	$759.90M	$8.25	46.87
Bio-Techne	$1.22B	9.33	$181.86M	$1.15	62.88

Bio-Rad Laboratories currently has a consensus price target of $343.33, suggesting a potential downside of 11.21%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.68%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Bio-Rad Laboratories has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Bio-Techne has a net margin of 14.97% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Techne's return on equity of 13.23% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Bio-Techne	14.97%	13.23%	10.61%

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Bio-Techne beats Bio-Rad Laboratories on 11 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Agilent Technologies?

Bio-Rad Laboratories (NYSE:BIO) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Agilent Technologies had 63 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 76 mentions for Agilent Technologies and 13 mentions for Bio-Rad Laboratories. Agilent Technologies' average media sentiment score of 1.16 beat Bio-Rad Laboratories' score of 0.02 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agilent Technologies	44 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has higher revenue and earnings than Bio-Rad Laboratories. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	4.00	$759.90M	$8.25	46.87
Agilent Technologies	$6.95B	6.25	$1.30B	$5.08	30.27

Bio-Rad Laboratories has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Agilent Technologies has a net margin of 19.53% compared to Bio-Rad Laboratories' net margin of 8.59%. Agilent Technologies' return on equity of 24.45% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Agilent Technologies	19.53%	24.45%	13.09%

Bio-Rad Laboratories currently has a consensus target price of $343.33, indicating a potential downside of 11.21%. Agilent Technologies has a consensus target price of $170.33, indicating a potential upside of 10.76%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Agilent Technologies beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Bio-Rad Laboratories has a net margin of 8.59% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

AMN Healthcare Services has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, AMN Healthcare Services had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for AMN Healthcare Services and 13 mentions for Bio-Rad Laboratories. AMN Healthcare Services' average media sentiment score of 0.48 beat Bio-Rad Laboratories' score of 0.02 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Rad Laboratories has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.49	-$95.70M	$2.68	12.77
Bio-Rad Laboratories	$2.58B	4.00	$759.90M	$8.25	46.87

AMN Healthcare Services currently has a consensus price target of $31.43, indicating a potential downside of 8.18%. Bio-Rad Laboratories has a consensus price target of $343.33, indicating a potential downside of 11.21%. Given AMN Healthcare Services' stronger consensus rating and higher possible upside, equities analysts clearly believe AMN Healthcare Services is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

AMN Healthcare Services beats Bio-Rad Laboratories on 9 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Bio-Rad Laboratories has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 11.21%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.78	$759.90M	$8.25	44.25
Bio-Rad Laboratories	$2.58B	4.00	$759.90M	$8.25	46.87

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Bio-Rad Laboratories had 13 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 13 mentions for Bio-Rad Laboratories and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.02 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
Bio-Rad Laboratories	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 10 of the 10 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIO vs. The Competition

Export

Metric	Bio-Rad Laboratories	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.37B	$10.11B	$7.20B	$24.17B
Dividend Yield	N/A	1.46%	2.54%	3.72%
P/E Ratio	46.87	62.83	272.59	29.84
Price / Sales	4.00	111.81	624.04	20.69
Price / Cash	38.69	26.70	28.74	19.75
Price / Book	1.40	5.44	11.05	4.82
Net Income	$759.90M	$56.67B	$3.47B	$1.07B
7 Day Performance	-0.88%	-1.52%	0.27%	-1.04%
1 Month Performance	18.80%	8.39%	8.28%	1.56%
1 Year Performance	29.59%	24.07%	24.14%	12.92%

Bio-Rad Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIO Bio-Rad Laboratories	1.6301 of 5 stars	$386.68 -0.3%	$343.33 -11.2%	+29.6%	$10.37B	$2.58B	46.87	7,450
RGEN Repligen	3.2358 of 5 stars	$181.62 +0.3%	$166.43 -8.4%	+48.0%	$10.22B	$785.10M	248.79	2,000	Positive News
TECH Bio-Techne	3.4805 of 5 stars	$72.39 +0.1%	$68.92 -4.8%	+32.4%	$11.34B	$1.22B	62.95	3,100	Positive News
A Agilent Technologies	4.7777 of 5 stars	$153.37 -3.5%	$160.24 +4.5%	+22.4%	$44.91B	$6.95B	30.80	18,100	Positive News Earnings Report High Trading Volume
AMN AMN Healthcare Services	2.2173 of 5 stars	$34.50 +0.1%	$31.43 -8.9%	+64.8%	$1.33B	$3.43B	12.87	2,664	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BIO) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Does the media prefer BIO or RGEN?

Which has stronger valuation and earnings, BIO or RGEN?

Do analysts prefer BIO or RGEN?

Do institutionals & insiders believe in BIO or RGEN?

Is BIO or RGEN more profitable?

Which has more risk and volatility, BIO or RGEN?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Does the media refer more to BIO or TECH?

Which has stronger valuation and earnings, BIO or TECH?

Do analysts prefer BIO or TECH?

Which has more volatility and risk, BIO or TECH?

Is BIO or TECH more profitable?

Do institutionals and insiders hold more shares of BIO or TECH?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Does the media prefer BIO or A?

Which has higher valuation and earnings, BIO or A?

Which has more volatility and risk, BIO or A?

Do insiders and institutionals hold more shares of BIO or A?

Is BIO or A more profitable?

Do analysts recommend BIO or A?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Is AMN or BIO more profitable?

Which has more risk & volatility, AMN or BIO?

Does the media favor AMN or BIO?

Do institutionals & insiders hold more shares of AMN or BIO?

Which has higher earnings and valuation, AMN or BIO?

Do analysts rate AMN or BIO?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Which has more volatility and risk, BIO.B or BIO?

Do analysts recommend BIO.B or BIO?

Which has higher valuation and earnings, BIO.B or BIO?

Do insiders and institutionals hold more shares of BIO.B or BIO?

Does the media prefer BIO.B or BIO?

Is BIO.B or BIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools